Epigenetics is a stream of genetics that involves the study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect the cellular ability to read genes without being affected by changes in the genotype Epigenetics results into changes in the organisms’ phenotype rather than the genotype, wherein the underlying DNA or RNA sequence remains unchanged. The global epigenetics market accounted for $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023. Research Beam Model: Research Beam Product ID: 1600768 5370 USD New
Epigenetics Market Size Analysis Report By AMR | 2023
 

Epigenetics Market by Product [Enzymes (DNA Ligases, DNA Polymerases, Other DNA-modifying Enzymes), Kits & Assays (Bisulfite Conversion Kits, Chip-Seq Kits, Deep Sequencing Kits, Methyltransferase Assays, Histone Assays, Immunoprecipitation Kits), Instruments (Mass Spectrometers, Next-generation Sequencers, qPCRs, and Sonicators), and Reagents (Antibodies, Buffers, Histones, Magnetic Beads, Primers, and Other Epigenetics Reagents)], Application (Oncology and Non-oncology Diseases, Developmental Biology, Drug Discovery, and Others), and End User [Academic & Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations (CROs)] - Global Opportunity Analysis and Industry Forecast, 2017-2023

Epigenetics Market by Product [Enzymes (DNA Ligases, DNA Polymerases, Other DNA-modifying Enzymes), Kits & Assays (Bisulfite Conversion Kits, Chip-Seq

Category : Diagnostic and Biotech
Published On : May  2017
Pages : 185

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Epigenetics is a stream of genetics that involves the study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect the cellular ability to read genes without being affected by changes in the genotype Epigenetics results into changes in the organisms’ phenotype rather than the genotype, wherein the underlying DNA or RNA sequence remains unchanged. The global epigenetics market accounted for $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023.

Epigenetic alterations are essential for development; they are dynamic and change with respect to the environmental stimuli. However, these changes can also be stable and could be passed on from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, thereby making it one of the most crucial fields of developmental genetics and molecular biology.

High incidence of cancer; increase in R&D activities; surge in investments funding, rise in epigenetic applications for non-oncology diseases; and growth in partnership between academic, pharmaceutical, and biotechnology companies cumulatively supplement the growth of the global epigenetics market. However, high cost of instruments and lack of trained professionals impede the growth of this market. Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players.

The epigenetics market is segmented based on product, application, end user, and geography. Based on product, it is divided into enzymes, kits & assays, instruments, and reagents. Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits & assays are further subdivided into bisulfite conversion kits, chip-seq kits, deep sequencing kits, methyltransferase assays, histone assays, immunoprecipitation kits & other epigenetic kits. Based on instruments, the market is further sub segmented into mass spectrometers, next-generation sequencers, qPCRs, and sonicators & other instruments. Reagents are further divided into antibodies, buffers, histones, magnetic beads, primers, and other epigenetics reagents.

On the basis application, the market is classified into oncology and non-oncology. Oncology is further sub segmented into solid tumors & liquid tumors. Non-oncology applications include inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications. On the basis of end user, the market is classified into academic & research institutes, pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global epigenetics market and the current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on application assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

KEY PLAYERS PROFILED

  • Abcam plc.
  • Illumina
  • QIAGEN N.V.
  • Epizyme, Inc.
  • New England Biolabs, Inc.
  • Merck & Co.,
  • Thermo Fisher Scientific, Inc.
  • Active Motif,
  • Diagenode, Inc.
  • Zymo Research Corporation

KEY MARKET SEGMENTS

By Product

  • Enzymes
    • DNA Ligases
    • DNA Polymerases
    • Other DNA-modifying Enzymes
    • Acetylases
    • Methyltransferases
    • Other Protein-modifying Enzymes
    • Reverse Transcriptase
    • RNA Ligases
    • Other RNA-modifying Enzymes
  • Kits & Assays
    • Bisulfite Conversion Kits
    • Chip-seq Kits
    • Deep Sequencing Kits
    • Methyltransferase Assays
    • Histone Assays
    • Immunoprecipitation Kits
    • Other Epigenetic Kits
  • Instruments
    • Mass Spectrometers
    • Next-generation Sequencers
    • qPCRs
    • Sonicators
    • Other Instruments
  • Reagents
    • Antibodies
    • Buffers
    • Histones
    • Magnetic Beads
    • Primers
    • Other Epigenetics Reagents

By Application

  • Oncology
    • Solid Tumors
    • Liquid Tumors
  • Non-oncology
    • Inflammatory Diseases
    • Metabolic Diseases
    • Infectious Diseases
    • Cardiovascular Diseases
    • Developmental Biology
    • Drug Discovery
    • Others

By End User

  • Academic & Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

The other players in the value chain include (profiles not included in the report)

  • Domainex
  • CellCentric Ltd.
  • Chroma Therapeutics Ltd.
  • Eisai Co. Ltd.
  • Novartis International AG
  • Oncolys Biopharma Inc.
  • Syndax Pharmaceuticals, Inc.
  • Valirx plc.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS

3.4.1. Patent analysis by year
3.4.2. Patent analysis by region

3.5. PORTERS FIVE FORCES ANALYSIS
3.6. MARKET DYNAMICS

3.6.1. Drivers
3.6.2. Restraints
3.6.3. Opportunities

CHAPTER 4 GLOBAL EPIGENETICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size & forecast

4.2. KITS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast
4.2.4. ChIP sequencing Kits

4.2.4.1. Market size and forecast

4.2.5. Bisulfite conversion kits

4.2.5.1. Market size and forecast

4.2.6. Whole genome amplification kits

4.2.6.1. Market size and forecast

4.2.7. 5-hmC & 5-mC analysis kits

4.2.7.1. Market size and forecast

4.2.8. RNA sequencing kits

4.2.8.1. Market size and forecast

4.2.9. Other epigenetics kits

4.2.9.1. Market size and forecast

4.3. REAGENTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast
4.3.4. Antibodies

4.3.4.1. Market size and forecast

4.3.5. Magnetic beads

4.3.5.1. Market size and forecast

4.3.6. Histones

4.3.6.1. Market size and forecast

4.3.7. Buffers

4.3.7.1. Market size and forecast

4.3.8. Primers

4.3.8.1. Market size and forecast

4.3.9. Other epigenetics reagents

4.3.9.1. Market size and forecast

4.4. ENZYMES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size & forecast
4.4.4. DNA Polymerase

4.4.4.1. Market size and forecast

4.4.5. Other DNA-modifying enzymes

4.4.5.1. Market size and forecast

4.4.6. DNA ligase

4.4.6.1. Market size and forecast

4.4.7. Methyltransferase

4.4.7.1. Market size and forecast

4.4.8. Acetylase

4.4.8.1. Market size and forecast

4.4.9. Reverse transcriptase

4.4.9.1. Market size and forecast

4.4.10. Other protein-modifying enzymes

4.4.10.1. Market size and forecast

4.4.11. RNA ligase

4.4.11.1. Market size and forecast

4.4.12. Other RNA-modifying enzymes

4.4.12.1. Market size and forecast

4.5. INSTRUMENTS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size & forecast
4.5.4. Next generation sequencer

4.5.4.1. Market size and forecast

4.5.5. qPCR

4.5.5.1. Market size and forecast

4.5.6. Mass spectrometer

4.5.6.1. Market size and forecast

4.5.7. Sonicator

4.5.7.1. Market size and forecast

4.5.8. Other instruments

4.5.8.1. Market size and forecast

CHAPTER 5 ENERGY EPIGENETICS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size & forecast

5.2. ONCOLOGY

5.2.1. Market size & forecast
5.2.1. Solid tumor

5.2.1.1. Market size and forecast

5.2.2. Liquid tumor

5.2.2.1. Market size and forecast

5.3. NON-ONCOLOGY

5.3.1. Market size & forecast
5.3.2. Metabolic disease

5.3.2.1. Market size and forecast

5.3.3. Infectious disease

5.3.3.1. Market size and forecast

5.3.4. Inflammatory disease

5.3.4.1. Market size and forecast

5.3.5. Cardiovascular disease

5.3.5.1. Market size and forecast

5.3.6. Other applications

5.3.6.1. Market size and forecast

CHAPTER 6 GLOBAL EPIGENETICS MARKET, BY END USERS

6.1. OVERVIEW

6.1.1. Market size & forecast

6.2. ACADEMIC & GOVERNMENT RESEARCH INSTITUTE

6.2.1. Market size & forecast

6.3. PHARMACEUTICAL COMPANY

6.3.1. Market size & forecast

6.4. BIOTECHNOLOGY COMPANY

6.4.1. Market size & forecast

6.5. CONTRACT RESEARCH ORGANIZATION (CRO)

6.5.1. Market size & forecast

CHAPTER 7 EPIGENETICS MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ILLUMINA, INC

8.1.1. Operating business segments
8.1.2. Business performance

8.2. THERMO FISHER SCIENTIFIC, INC

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. ABCAM PLC

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. EPIZYME, INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. NEW ENGLAND BIOLABS, INC. (NEB)

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. QIAGEN N.V.,

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. MERCK & CO., (MERCK)

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. ACTIVE MOTIF

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. DIAGENODE, INC.

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. ZYMO RESEARCH CORPORATION (ZYMO)

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL EPIGENETICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 2. GLOBAL EPIGENETICS KITS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3. EPIGENETICS CHIP SEQUENCING KITS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. EPIGENETICS BISULFITE CONVERSION KITS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 5. EPIGENETICS WHOLE GENOME AMPLIFICATION KITS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. EPIGENETICS 5-HMC & H-MC ANALYSIS KITS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. EPIGENETICS RNA SEQUENCING KITS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 8. OTHER EPIGENETICS KITS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL EPIGENETICS REAGENTS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 10. EPIGENETICS ANTIBODIES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. EPIGENETICS MAGNETIC BEADS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. EPIGENETICS HISTONES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. EPIGENETICS BUFFERS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. EPIGENETICS PRIMERS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. OTHER EPIGENETICS REAGENTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL EPIGENETICS ENZYMES MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 17. EPIGENETICS DNA POLYMERASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. EPIGENETICS OTHER DNA MODIFYING ENZYMES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. EPIGENETICS DNA LIGASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. EPIGENETICS METHYLTRANSFERASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 21. EPIGENETICS ACETYLASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. EPIGENETICS REVERSE TRANSCRIPTASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. EPIGENETICS OTHER PROTEIN-MODIFYING ENZYMES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 24. EPIGENETICS RNA LIGASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 25. EPIGENETICS OTHER RNA MODIFYING ENZYMES ENZYMES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. GLOBAL EPIGENETICS INSTRUMENTS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 27. EPIGENETICS NEXT GENERATION SEQUENCER MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 28. EPIGENETICS QPCR MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 29. EPIGENETICS MASS SPECTROMETER MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 30. EPIGENETICS SONICATOR MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. EPIGENETICSOTHER INSTRUMENTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 32. GLOBAL EPIGENETICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. GLOBAL ONCOLOGY EPIGENETICS MARKET, BY APPLICATION TYPE, 2016-2023 ($MILLION)
TABLE 34. EPIGENETICS SOLID TUMOR MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 35. EPIGENETICS LIQUID TUMOR MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 36. GLOBAL NON-ONCOLOGY EPIGENETICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. EPIGENETICS METABOLIC DISEASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 38. EPIGENETICS INFECTIOUS DISEASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 39. EPIGENETICS INFLAMMATORY DISEASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 40. EPIGENETICS CARDIOVASCULAR DISEASE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 41. EPIGENETICS OTHER APPLICATION MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 42. GLOBAL EPIGENETICS MARKET, BY END USERS, 2016-2023 ($MILLION)
TABLE 43. ACADEMIC & GOVERNMENT RESEARCH INSTITUTE EPIGENETICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 44. PHARMACEUTICAL COMPANY EPIGENETICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 45. BIOTECHNOLOGY COMPANY EPIGENETICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 46. CRO EPIGENETICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 69. ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 70. ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 71. ASIA-PACIFIC EPIGENETICS KITS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 72. ASIA-PACIFIC EPIGENETICS REAGENTS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC EPIGENETICS ENZYMES MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC EPIGENETICS INSTRUMENTS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 76. ASIA-PACIFIC ONCOLOGY EPIGENETICS MARKET, BY APPLICATION TYPE, 2016-2023 ($MILLION)
TABLE 77. ASIA-PACIFIC NON-ONCOLOGY EPIGENETICS MARKET, BY APPLICATION TYPE, 2016-2023 ($MILLION)
TABLE 79. LAMEA EPIGENETICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 80. LAMEA EPIGENETICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 81. LAMEA EPIGENETICS KITS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 82. LAMEA EPIGENETICS REAGENTS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 83. LAMEA EPIGENETICS ENZYMES MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 84. LAMEA EPIGENETICS INSTRUMENTS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 85. LAMEA EPIGENETICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 86. LAMEA ONCOLOGY EPIGENETICS MARKET, BY APPLICATION TYPE, 2016-2023 ($MILLION)
TABLE 87. LAMEA NON-ONCOLOGY EPIGENETICS MARKET, BY APPLICATION TYPE, 2016-2023 ($MILLION)
TABLE 89. ILLUMINA, INC: COMPANY SNAPSHOT
TABLE 90. THERMO FISHER SCIENTIFIC, INC: COMPANY SNAPSHOT
TABLE 91. ABCAM PLC: COMPANY SNAPSHOT
TABLE 92. EPIZYME, INC.: COMPANY SNAPSHOT
TABLE 93. NEB: COMPANY SNAPSHOT
TABLE 94. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 95. MERCK: COMPANY SNAPSHOT
TABLE 96. ACTIVE MOTIF: COMPANY SNAPSHOT
TABLE 97. DIAGENODE, INC.: COMPANY SNAPSHOT
TABLE 98. ZYMO: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. EPIGENETICS MARKET: MARKET SEGMENATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL DNA SEQUENCING MARKET, BY APPLICATION
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 5. TOP PLAYER POSITIONING: GLOBAL EPIGENETICS MARKET
FIGURE 6. PATENT ANALYSIS BY REGION
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. EPIGENETICS MARKET: PRODUCT SEGMENATION
FIGURE 13. U.S. EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 14. CANADA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 15. MEXICO EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 16. GERMANY EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 18. UK EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 24. AUSTRALIA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 26. SOUTH KOREA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 27. TAIWAN EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 28. REST OF ASIA-PACIFIC EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 29. BRAZIL EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 30. TURKEY EPIGENETICS MARKET, 2016-20223 ($MILLION)
FIGURE 31. SAUDI ARABIA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 32. REST OF LAMEA EPIGENETICS MARKET, 2016-2023 ($MILLION)
FIGURE 33. ILLUMINA, INC: NET SALES, 2014-2017 ($MILLION)
FIGURE 34. ILLUMINA, INC: REVENUE BY SEGMENT, 2015 (%)
FIGURE 35. THERMO FISHER SCIENTIFIC, INC: NET SALES, 2014-2017 ($MILLION)
FIGURE 36. THERMO FISHER SCIENTIFIC, INC: REVENUE BY SEGMENT, 2015 (%)
FIGURE 37. THERMO FISHER SCIENTIFIC, INC: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 38. ABCAM PLC: NET SALES, 2014-2017 ($MILLION)
FIGURE 39. ABCAM PLC.: REVENUE BY SEGMENT, 2015 (%)
FIGURE 40. ABCAM PLC.: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 41. EPIZYME, INC.: NET SALES, 2014-2017 ($MILLION)
FIGURE 42. EPIZYME, INC.: REVENUE BY SEGMENT, 2015 (%)
FIGURE 43. EPIZYME, INC.: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 44. NEB: NET SALES, 2014-2017 ($MILLION)
FIGURE 45. NEB: REVENUE BY SEGMENT, 2015 (%)
FIGURE 46. NEB: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 47. QIAGEN N.V: NET SALES, 2014-2017 ($MILLION)
FIGURE 48. QIAGEN N.V: REVENUE BY SEGMENT, 2015 (%)
FIGURE 49. QIAGEN N.V: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 50. MERCK: NET SALES, 2014-2017 ($MILLION)
FIGURE 51. MERCK: REVENUE BY SEGMENT, 2015 (%)
FIGURE 52. MERCK: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 53. ACTIVE MOTIF: NET SALES, 2014-2017 ($MILLION)
FIGURE 54. ACTIVE MOTIF: REVENUE BY SEGMENT, 2015 (%)
FIGURE 55. ACTIVE MOTIF: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 56. DIAGENODE, INC: NET SALES, 2014-2017 ($MILLION)
FIGURE 57. DIAGENODE, INC: REVENUE BY SEGMENT, 2015 (%)
FIGURE 58. DIAGENODE, INC: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 59. ZYMO: NET SALES, 2014-2017 ($MILLION)
FIGURE 60. ZYMO: REVENUE BY SEGMENT, 2015 (%)
FIGURE 61. ZYMO: REVENUE BY GEOGRAPHY, 2015 (%)

Enquiry Before Buy